• Users Online: 1090
  • Print this page
  • Email this page
Year : 2022  |  Volume : 13  |  Issue : 3  |  Page : 314-316

Serious adverse effects following use of liraglutide in individuals with type 2 diabetes

MGM Healthcare, No. 72 Nelson Manickam Road, Chennai 600029, Tamil Nadu, India

Correspondence Address:
Prof. Georgi Abraham
Department of Nephrology, MGM Healthcare, No. 72 Nelson Manickam Road, Chennai 600029, Tamil Nadu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jod.jod_78_22

Rights and Permissions

Glucagon-like peptide-1 (GLP-1) analog liraglutide is extensively used for type 2 diabetes mellitus, especially in those with overweight and cardiovascular risk factors. The risk benefit ratio favors their use. The life-threatening complications such as cholecystitis and pancreatitis are infrequently reported. Here we report two patients who developed recurrent gallstone diseases with cholestatic jaundice and acute pancreatitis in a male patient and an asymptomatic large gallstone stone in a female kidney transplant patient with no previous evidence of gallstone disease. This highlights the importance of surveillance screening in patients on liraglutide to prevent the development of complications.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded65    
    Comments [Add]    

Recommend this journal